Iron status in patients with chronic heart failure

Area of Science:

• Cardiology
• Iron Metabolism
• Biomarkers

Background:

• Iron status and its regulation in heart failure (HF) are not fully understood.
• Hepcidin, a key regulator of iron metabolism, may influence HF progression.
• Investigating iron status changes and their link to prognosis in HF is crucial.

Purpose of the Study:

• To examine iron status in patients with systolic HF.
• To correlate iron status with HF disease progression.
• To assess the association between iron status and long-term HF prognosis.

Main Methods:

• Assessed serum biomarkers of iron status (ferritin, Tsat, sTfR, hepcidin) in 321 HF patients and 66 controls.
• Categorized patients by NYHA class to evaluate disease severity.
• Utilized multivariable Cox models to determine prognostic significance.

Main Results:

• Asymptomatic HF patients had elevated ferritin and hepcidin compared to controls.
• Advanced HF (higher NYHA class) was associated with iron deficiency, iron-restricted erythropoiesis, and inflammation.
• Decreased circulating hepcidin levels correlated with increased 3-year mortality in HF patients.

Conclusions:

• Elevated hepcidin characterizes early HF, preceding anemia or inflammation.
• HF progression leads to declining hepcidin and the development of iron deficiency.
• Low hepcidin is an independent predictor of poor outcomes in heart failure.